Archive: April 2017
Melanoma
The Best Treatments to Use After Checkpoint Inhibition in Melanoma
Grant McArthur, MBBS, PhD
H&O Which patients with melanoma are candidates for checkpoint inhibition? GM All patients with unresectable metastatic melanoma—stage IV and unresectable stage III disease—are candidates for checkpoint […]
Breast Cancer
Antibody-Drug Conjugates in Breast Cancer
Aditya Bardia, MD, MPH
H&O What are antibody-drug conjugates (ADCs)? AB ADCs are drugs that contain an antibody linked to a chemotherapy agent. Accordingly, they have 3 components: an antibody […]
Leukemia
Treatment of Acute Lymphoblastic Leukemia in Older Adults: Now and the Future
Musa Yilmaz, MD, Hagop Kantarjian, MD, and Elias Jabbour, MD
Abstract: Acute lymphoblastic leukemia (ALL) is an uncommon disease with poor outcomes in older patients. Although intensive chemotherapy can induce complete responses in older patients, […]
Myeloma
Myeloma Bone Disease: Pathogenesis and Treatment
Elizabeth K. O’Donnell, MD, and Noopur S. Raje, MD
Abstract: Bone involvement manifesting as osteolytic bone disease (OBD) or osteopenia is one of the defining features of multiple myeloma (MM). Osteolytic lesions develop in […]
Clinical Update
Advances in the Management of Patients With Carcinoid Syndrome
Matthew H. Kulke, MD
H&O What are the symptoms of carcinoid syndrome? MK Carcinoid syndrome can occur in patients who have carcinoid tumors. Carcinoid tumors have the ability to […]
Counterpoints
What Should Frontline Treatment Be in Chronic Myeloid Leukemia?
Stephanie Glancy Lee, MD, FRCPC, Jeffrey H. Lipton, PhD, MD, FRCPC, Carmen Fava, MD, PhD, and Giuseppe Saglio, MD
The US Food and Drug Administration has approved 3 tyrosine kinase inhibitors (TKIs) for use as frontline treatment in chronic myeloid leukemia (CML): imatinib, dasatinib (Sprycel, […]
Drug Development
How Direct-to-Patient Research Can Improve Interest in Clinical Trials
Deborah Collyar
H&O What are the challenges involved in patient recruitment and retention in traditional clinical trials? DC There are so many challenges. For example, most traditional […]
Lymphoma
The Use of CAR T Cells in Diffuse Large B-Cell Lymphoma and Mantle Cell Lymphoma
Peter Martin, MD, MS
H&O Why are new treatments needed in DLBCL and MCL? PM Existing therapies are ineffective in a subset of patients or have toxicities that make […]
Kidney Cancer
Genetic Conditions Associated With a Predisposition to Kidney Cancer
Based on a presentation by W. Marston Linehan, MD, at the ASCO Genitourinary Cancers Symposium Scientists have identified at least 13 genes that predispose patients […]
Hem/Onc News
News
Clinical Advances in Hematology & Oncology April 2017, Volume 15, Issue 4 By Devon Schuyler Pembrolizumab Improves Survival in Advanced Urothelial Cancer Pembrolizumab (Keytruda, Merck) improved […]
Letter From the Editor
Letter from the Editor: Affordable Care?
Brad S. Kahl, MD
Nobody knew health care could be so complicated. – President Donald Trump Actually, lots of people did. In the president’s defense, I am sure he never […]